SpikImm, a Biotech Company Founded by Truffle Capital and Institut Pasteur, Announces That Its Monoclonal Antibody Neutralises All SARS-COV-2 Variants of Concern, Including Omicron (BA.1 and BA.2)

Results are available as preprint and have been submitted in an international peer-reviewed journal. https://www.biorxiv.org/content/10.1101/2022.04.01.486719v1 SpikImm expects to initiate

Related Keywords

Paris ,France General ,France ,French ,Institut Pasteur Inserm ,Institut Pasteur ,Philippe Pouletty ,Hugo Mouquet ,Patrick Kron ,Armand Rigaudy ,Bernard Louis Roques ,Antoine Pau ,Louis Pasteur ,Primatice Conseil ,Institut Pasteur International Network ,Twitter ,Life Sciences Medtech ,Humoral Immunology ,Emergency Use Authorization ,Scientific Director ,Senior Partner ,Truffle Capital ,Institut Pasteur International ,Nobel Prize ,European Venture Capital ,Life Sciences ,Spikimm ,Biotech ,Company ,Wounded ,Truffle ,Capital ,Institut ,Pasteur ,Nnounces ,Hat ,Monoclonal ,Ntibody ,Neutralises ,Cars ,Variants ,Concern ,Ncluding ,Micron ,